In 2018, more than 50% of our clients experienced a negative overall drug trend. Our trend report highlights our industry-leading results in managing specialty and chronic conditions—two main drivers of escalating drug costs for pharmacy plans.
Our success engaging with physicians and patients helped drive our industry-leading specialty pharmacy trend. Our engagement strategy is anchored by WellConnect, a personalized messaging tool.
WellManaged – Diabetes Program
One of the most prevalent chronic conditions, members in our WellManaged Diabetes program experienced a 2.5% trend. Clients not using our specialized program experienced a 13% trend.
WellManaged – Pain Inflammation
Clients in our WellManaged Opioids and Hyperinflationary Drug Programs experienced substantial utilization and unit cost decreases in the Pain Inflammation category.